Product Information

ABILIFY 5 MG TABLET is a brand product labeled by Otsuka America Pharmaceutical Inc., priced at $18.7122 per EA under NDC 59148000713. Its NADAC has been published 605 times since Nov 28, 2013.

FDA first approved this application on Nov 15, 2002. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the ARIPIPRAZOLE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

ABILIFY 5 MG TABLET

ARIPIPRAZOLE
$18.7122per EA
High Outlier

Strength

5 mg/1

NDC

59148000713

Classification

Brand

Dosage Form

TABLET

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

ARIPIPRAZOLE

Approval Type

New Drug (NDA)

FDA Application

NDA021436

FDA Approved

11/15/2002

TE Code

AB

On Market Since

11/15/2002

Pharmacological Classes

Price Statistics

The NADAC for ABILIFY 5 MG TABLET has been published 605 times since Nov 28, 2013, and over the history we have for it it has declined 14.9%. The table below summarizes its recorded NADAC range and movement.

Current price$18.7122 per EA
All-time high$28.9020 (Aug 10, 2016)
All-time low$18.5592 (Aug 20, 2025)
52-week high$18.7122
52-week low$18.5592
Median price$28.4389
Average price$25.0983
Largest weekly change-23.0% (Oct 6, 2021)
Weeks tracked605
Tracking sinceNov 28, 2013

Price History

1W

+0.0%

1M

+0.3%

3M

+0.1%

6M

+0.1%

1Y

+0.8%

3Y

+0.2%

5Y

-34.4%

All

-14.9%

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of ABILIFY 5 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for ABILIFY 5 MG TABLET, manufactured by Otsuka America Pharmaceutical Inc., is $18.7122 per EA (NDC 59148000713), effective Aug 19, 2026.

How has the price of ABILIFY 5 MG TABLET changed over time?

Over the history we have for it, the NADAC for ABILIFY 5 MG TABLET has declined 14.9%. It has been tracked across 605 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for ABILIFY 5 MG TABLET?

Since Nov 28, 2013, the NADAC for ABILIFY 5 MG TABLET has ranged from a low of $18.5592 (Aug 20, 2025) to a high of $28.9020 (Aug 10, 2016), with a median of $28.4389 per EA.

Are there cheaper alternatives to ABILIFY 5 MG TABLET?

Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ARIPIPRAZOLE 5 MG TABLET, is $0.1059 per EA — about 99% below ABILIFY 5 MG TABLET.

Who manufactures ABILIFY 5 MG TABLET?

ABILIFY 5 MG TABLET (NDC 59148000713) is labeled by Otsuka America Pharmaceutical Inc., and CMS classifies it as a brand product.